Kornimate/medical-research-clean huggingface dataset:
detecting dopaminergic deficits in individuals at-risk for parkinsonism

Conditions: Parkinson Disease; Gaucher Disease; Idiopathic Rapid Eye Movement Sleep Disorder

Summary: the purpose of this study is to determine if participants have changes in dopamine cells in their brain using datscan™ brain imaging. dopamine cell loss occurs in parkinson's disease (pd) and other degenerative parkinsonian disorders, but does not occur in most other movement disorders such as essential tremor or dystonia. datscan, which is also known as 123i-ioflupane, is a new compound that has been developed by general electric, inc. and has been approved by the us food and drug administration (fda) to help doctors detect changes in dopamine. this test is performed by injecting datscan into a vein in the arm, and after a few hours, a large amount of datscan temporarily accumulates in an area of the brain where there are a lot of dopamine brain cells. because datscan contains a small amount of radioactive iodine, it allows doctors to use a special machine called single photon emission computed tomography (spect) scanning to detect the location and amount of radioactivity in the brain and help determine if there are changes in brain dopamine. it is hoped that this study will help doctors detect the presence of dopamine changes even before symptoms are present. this study will evaluate datscan in people with pd, those who are at risk for developing pd (e.g., those with idiopathic rapid eye movement sleep disorder (irbd) and those who are heterozygous or homozygous for gaucher's disease (gba) mutations) and those who are healthy volunteers.


Eligibility criteria:
inclusion criteria: * written consent prior to study by the subject or their surrogate * subjects \>/= 18 years and\</=85 years * diagnosis of parkinson's disease, family history of parkinson's disease, idiopathic rapid eye movement sleep behavioral disorder, age-matched controls, gaucher's disease or carrier of gaucher's gene mutation * females using adequate methods of birth control or not of childbearing potential exclusion criteria: * any clinically significant acute or unstable physical or psychological disease based on medical history or screening physical examination * any exposure to investigational drugs within 4 weeks prior to visit 1 * any exposure to radiopharmaceuticals within 4 weeks prior to visit 1 * pregnancy * breastfeeding * severe swallowing problems * known sensitivity or allergy to iodine containing products * advanced liver or renal disease

Keywords: parkinson disease idiopathic rapid eye movement sleep disorder gaucher disease healthy volunteer
portable visual guidance system phase ii

Conditions: Asperger Syndrome; High Functioning Autism

Summary: abstract: in phase i, we designed and tested a portable visual guidance system (pvgs), which combines a pda - for user guidance - and an internet website - for linking the user to an educational support team. use of the pvgs 1) significantly improved the in vivo social pragmatics of students diagnosed with aspergers syndrome/higher functioning autism (as/hfa); 2) revealed additional ways of improving social pragmatics; and 3) improved activity management in scheduling and vocational tasks. in phase ii, we will focus on social pragmatics and two closely related skills: feelings management and assignment management. we aim to: 1. replicate phase i success in the most educational setting for as/hfa high school aged students: mainstream school inclusion classes. 2. replicate phase i findings more efficiently, with a less highly trained, on-site coaching staff and with more distant (non-site) expert supervision of that staff. 3. contrast the outcomes of the curriculum with a diagnosis-matched wait-list control group. 4. develop and implement software that will enable on-site staff to create and modify individualized guidance and monitoring screens as needs arise. 5. design a commercially attractive package of software, video training, video-conferenced support, and manuals. 6. complete the translation of the symtrend website and all the above tools into spanish. significance: successful completion of phase ii will: 1. provide a very effective and comprehensive system for teaching social pragmatics and related management skills to as/hfa persons in an inclusion context. 2. provide a means of evaluating iep effectiveness, thereby enabling a better use of special education funds and a reduction of litigation over iep plan appropriateness and utility. 3. provide substantial support for our theoretical rationale for curriculum building in special education - a rationale that can guide the formulation of ieps. 4. provide a theoretical rationale, an intervention framework, and intervention support technology that can be extended to cognitive behavioral treatment of other neuropsychiatric disorders and can be adapted for other forms of healthcare guidance. 5. provide an investigative system, as well as an intervention system, for tracking behavioral change in studies of frontal lobe and limbic neuroplasticity in neuropsychiatric disorders.


Eligibility criteria:
inclusion criteria: * ages 11-21 * diagnosis of as/hfa * a student at participating high school and middle schools (newton, ma; brockton, ma; veritas christian academy, fletcher, nc; durham, nc. exclusion criteria: * participating in another study
assessment of prognosis and myocardial reperfusion in patients with st-segment-elevation myocardial infarction (stemi) according to coronary atherosclerotic burden.

Conditions: STEMI - ST Elevation Myocardial Infarction (MI)

Summary: in the current literature, it has been widely demonstrated that the extend of coronary atherosclerotic burden is associated with adverse long-term outcomes. little is known about the impact of atheroma burden and either myocardial reperfusion and short-term outcomes after st-segment elevation myocardial infarction (stemi). several angiographic scores have been used to measure the extend and severity of coronary atheroma. the syntax score and the gensini score have been shown to be independent predictors of cardiovascular events and mortality in stable coronary artery disease as well as in myocardial infarction. this research therefore aims to assess the impact of overall coronary atherosclerotic burden, measured by two angiographic scores (syntax score and gensini score), both before and after primary percutaneous angioplasty, in patients with stemi according to different clinical subgroups.


Eligibility criteria:
inclusion criteria: - patients presenting with stemi and treated with primary pci (ppci) at the university hospital of nancy between 2003 and 2023. exclusion criteria: - patients with missing or incomplete coronary angiogram.
aortic valve dynamics during exercise after valve sparing root replacement surgery

Conditions: Aneurysm Aortic Root; Aortic Valve, Bicuspid

Summary: aortic valve sparing operations are applied in patients with a non-calcified tricuspid or bicuspid aortic valve associated with a root aneurysm, in order to preserve the valve, and avoid new aortic dilatation by stabilizing the aortic valve anulus with a graft prosthesis. this results in a normal functioning aortic valve, with a low forward gradient across the left ventricular outflow tract. little is known about how the repaired aortic valve behaves in conditions of controlled exercise, and how the gradients across the valve change during exercise.

in a cohort of patients operated on since 2000 with a valve sparing operation for aortic root aneurysm in the department of cardiac surgery of the university hospital ghent, belgium, and with gradients at rest across the aortic valve of \<20mmhg, a graded exercise test on a bicycle (stepwise increase of afterload) will be performed, and the gradient across the aortic valve will be monitored by transthoracic echocardiography at each exercise level. patients with tricuspid and bicuspid valves will be compared. an age matched, unoperated, and asymptomatic control group with normal functioning tricuspid and bicuspid valves will be examined with the same exercise protocol. the purpose of the study is the description of the gradients across the aortic valve during exercise, and the discrimination of risk factors that may induce increased gradients. the hypothesis is that patients with bicuspid valves will demonstrate higher gradients than patients with tricuspid valves, in operated and unoperated individuals.

Eligibility criteria:
inclusion criteria: * been operated with a valve sparing root procedure in the university hospital ghent, belgium, since 2000 * being able to perform an exercise test on a reclining bicycle * normal left ventricular function exclusion criteria: * \ 60 years of age * peak gradient across the aortic valve at rest of \>20mmhg * decreased left ventricular function

Keywords: valve sparing procedure reimplantation
registry of guardant360® use and outcomes in people with advanced cancer

Conditions: Non-small Cell Lung Cancer Metastatic

Summary: the purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.

this is a prospective, descriptive registry of people with advanced cancer for whom a guardant360 assay has been ordered by their health care providers. the registry is divided into modules according to primary cancer diagnosis. module 1 includes subjects with advanced nsclc with additional modules added later in the study. all eligible people for whom blood for a guardant360 assay has been collected will be invited to participate in the registry. subject demographics and relevant medical history will be collected at the time of enrollment. information on tumor molecular testing, treatment decisions, and clinical outcomes from the time of enrollment will be collected in a prospective manner. the registry does not require any specific treatments or procedures but rather collects information on the treatment journey of each participant. subjects may participate in other clinical studies while also participating in geode.

Eligibility criteria:
general inclusion criteria: 1. 18 years of age or older 2. ability to provide written informed consent 3. blood collected for the most recent guardant360 test within 8 weeks prior to enrollment general exclusion criteria 1. pregnancy at the time of the qualifying guardant360 blood collection 2. history of the allogeneic organ or tissue transplant module 1 (non-small cell lung cancer) inclusion criteria 1. nsclc, confirmed by histology or cytology 2. advanced disease, defined as: stage iiib or iv nsclc at the time of the qualifying guardant360 blood collection; or for subjects with an initial diagnosis of stage i-iiia disease, nsclc that is recurrent or metastatic at the time of the qualifying guardant360 blood collection 3. one of the following conditions at the time of the qualifying guardant360 blood collection: * no prior systemic therapy for advanced disease or * all three of the following conditions: 1. a history of prior systemic therapy for advanced disease, 2. disease progression within the previous four weeks, \& 3. no new systemic therapy for advanced disease exclusion criteria subjects with a diagnosis or history of any cancer involving the lung that is not classified as nsclc, including but not limited to small cell carcinoma, neuroendocrine or carcinoid tumor, lymphoma, mesothelioma, metastatic non-lung carcinoma, or cancer of unknown primary.

Keywords: guardant health
weight management of dialysis patients

Conditions: Hemodialysis; Life Quality; Interdialytic Weight Gain; Cardiovascular Events; Hypertension; Dry Weight

Summary: the goal of this clinical trial is to improve the quality of life in hemodialysis patient. the main questions it aims to answer are: * \[improve the self-compliance of dialysis patients with weight management\] * \[alleviate the volume load of dialysis patients and reduce cardiovascular complications\] participants will be divided into two groups based on a weight management regimen： control group: received routine outpatient management. specific methods: the dialysis doctor registered the information of the patient\&#39;s weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management. intervention group: on the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. specific methods: same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. on this basis, a special wechat signal is set up to add patients or patients\&#39; family members as wechat friends and establish a wechat interaction platform with patients. in the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.


Eligibility criteria:
inclusion criteria: * age ≥18; * dialysis age ≥3 months; * survival ≥12 months; * patients themselves or family members can use wechat; * informed consent exclusion criteria: * have a cognitive or intellectual disability unable to read and understand sms; * have mental illness; * other serious complications occurred
platelets antiaggregation control enhancement (pace) study

Conditions: Bleeding; Blood Transfusion

Summary: many patients undergo cardiac surgery without proper suspension of antiaggregation drugs. this is blamed to increase dramatically bleeding and use of allogenic blood transfusions. the investigators test the hypothesis that routine use of aggregometry could show antiaggregated patient and lead to normalization of platelet function via administration of desmopressin thus limiting bleeding and transfusions.


Eligibility criteria:
inclusion criteria: * all patients undergoing surgical myocardial revascularization. exclusion criteria: * none.

Keywords: bleeding blood sparing procedure desmopressin aggregometry thromboelastography
pk study of sotagliflozin in subjects with hepatic impairment

Conditions: Hepatic Impairment; Healthy

Summary: to evaluate the effect of mild, moderate, or severe hepatic impairment on the pharmacokinetics (pk) of a single dose of 400 mg sotagliflozin (2 x 200-mg tablets) compared with healthy, demographically-matched subjects.


Eligibility criteria:
inclusion criteria: * adult male and female subjects ≥18 to ≤70 years of age * body mass index ≥18.0 to ≤36.0 kg/m2, inclusive, at screening * subjects with mild, moderate, or severe hepatic impairment * control group of matched healthy subjects * willing and able to provide written informed consent exclusion criteria: * presence of clinically significant physical, laboratory, or ecg findings that may interfere with any aspect of study conduct or interpretation of results * existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of sotagliflozin * history of any major surgery within 6 months * history of renal disease, or significantly abnormal kidney function test * women who are breastfeeding or are planning to become pregnant during the study
effect of ocrelizumab on neuroinflammation in multiple sclerosis as measured by 11c-pbr28 mr-pet imaging of microglia activation

Conditions: Multiple Sclerosis

Summary: using magnetic resonance-pet (mr-pet) imaging with \[11c\]pbr28, a second-generation 18kda translocator protein (tspo) radiotracer, we have previously demonstrated abnormally high tspo expression, indicative of microglia activation, across different brain tissue compartments of multiple sclerosis (ms) patients1. in this study, we propose to study the efficacy of ocrelizumab, a humanized monoclonal antibody that has been shown to decrease neuroinflammation in relapsing-remitting multiple sclerosis (rrms) and progressive multiple sclerosis (ms) patients. we will test these effects by studying a cohort of 24 ms patients (12 rrms, 12 progressive ms). participants will be studied before (within 3 months prior to initiating treatment) and after treatment with ocrelizumab (\~12 month follow up), a therapeutic drug that will be part of their standard medical care. we will use \[11c\]pbr28 to help determine changes in neuroinflammation. the purpose of this study is to determine the effects of ocrelizumab treatment on neuroinflammation by analyzing the uptake and distribution of \[11c\]pbr28 in individuals with multiple sclerosis. the specific aims of the current study are: 1. to assess whether treatment with ocrelizumab in subjects with either relapsing-remitting ms or progressive ms is associated with decreased \[11c\]pbr28 binding in the cortex and white matter (lesions and normal appearing white matter), suggesting reduced neuroinflammation. 2. to assess whether changes in neuroinflammation under ocrelizumab treatment, as measured by \[11c\]pbr28 uptake at 12-month follow up relative to baseline, are associated with changes in structural mr metrics of brain tissue damage including white matter lesion load, cortical atrophy, and demyelination in the cortex and in the normal-appearing white matter as measured by magnetization transfer ratio (mtr). 3. to explore whether changes in functional and structural imaging metrics under ocrelizumab are associated with changes in clinical outcome measures.


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. rrms and/or pms subtype 3. edss between 0 and 7.0 4. express at least one high-affinity (ala147) allele of the tspo receptor for pbr28 5. initiating ocrelizumab treatment within the next 3 months exclusion criteria: 1. hypersensitivity to trial medications 2. history of life-threatening reaction to ocrelizumab 3. acute or uncontrolled chronic medical condition 4. impaired hearing 5. claustrophobia 6. 300 lbs of greater (weight limit of mri table) 7. pregnancy or breastfeeding 8. sensitivity to imaging agents 9. contraindications to mri 10. use of benzodiazepines, topiramate, doxycycline, mynocicline
animal assisted therapy in a pediatric setting

Conditions: Developmental Delays; Global Developmental Delay; Stroke; Cancers; Seizures Disorders; Behavior Problems; Feeding Disorder; Developmental Delay in Feeding

Summary: the primary purpose for this study is to determine if children who receive occupational therapy while they are an inpatient in the hospital will be more motivated to participate in therapy as well as increase the amount of time they will work during that particular session when a therapy dog is present during their sessions. the investigators will also be collecting data regarding a child's heart rate and blood pressure prior to the session starting and ending to determine if having a therapy dog present also helps relax a child.

the primary objective of this study is to evaluate if a patient in the pediatric acute care setting receiving occupational therapy (ot) services in adjunct with animal assisted therapy (aat) are more motivated to actively participate in the therapy session for a longer period of time. methods: thirty inpatients will be recruited to participate in this study. this study will utilize a randomized crossover study design where the patients act as their own control. the treatment period for hospitalized patients will include an on off pattern of incorporating aat into their ot session. patients' participation of therapy will be assessed with a participation scale (see figure 2) and the ot session time. patients will be evaluated for ot and the therapist will determine goals based on functional status and needs of the particular patient. goals will be determined by providing a functional evaluation based upon occupational therapists clinical observation, developmental standards and current functional level of the patient. patients who are potential candidates for this study will be hospitalized at children's hospitals and clinics of minnesota on the st. paul campus. all inpatients stated to have decreased functional skills that have been referred by a physician to ot will be invited to participate this study. patients have a difficult time participating in various therapies due to emotional stress, anxiety, and feeling uncomfortable with the hospital environment. limited studies have demonstrated the value of aat used in conjunction with ot for children, regardless of diagnosis within the hospital setting. results of this study can justify the use of this valuable therapy not only for the selected population, but also for other disciplines such as physical and speech therapy.

Eligibility criteria:
inclusion criteria: * inpatient occupational therapy referrals * ages 0-21 years exclusion criteria: * patients who are uncomfortable with dogs * patients who exhibits violent behavior * animal allergies * patients are unable to work with a dog * patients who exhibit severe cognitive delays

Keywords: occupational therapy
short- and long-term health consequences of workers during consecutive days of heat stress

Conditions: Heat Stress; Fatigue

Summary: the purpose of this study is to measure fatigue and indicators of acute kidney injury during consecutive days of work in a hot environment.


Eligibility criteria:
inclusion criteria: * healthy individuals * regularly completes aerobic exercise at least 60 min per week exclusion criteria: * history of cardiovascular, metabolic, respiratory, neural, or renal disease * hypertensive or tachycardic during the screening visit (systolic blood pressure \> 139 mmhg, diastolic blood pressure \> 89 mmhg, heart rate \> 100 bpm) * current tobacco or nicotine use or previous regular use within the past 2 years * current or previous musculoskeletal injury limiting physical activity * taking medications with known thermoregulatory or cardiovascular effects (e.g., aspirin, beta blockers, diuretics, psychotropics, etc.) * a positive pregnancy test at any point during the study or currently breastfeeding * study physician discretion based on any other medical condition or medication